Cadrenal Therapeutics, Inc. Retained Earnings
Cadrenal Therapeutics, Inc. (CVKD) had Retained Earnings of -$44.78 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-08-13
- 2026-06-30: Retained Earnings (Accumulated Deficit) -$44.78M.
- 2026-03-31: Retained Earnings (Accumulated Deficit) -$41.46M.
- 2025-12-31: Retained Earnings (Accumulated Deficit) -$38.96M.
- 2025-09-30: Retained Earnings (Accumulated Deficit) -$35.92M.
| Period end | Retained Earnings (Accumulated Deficit) |
|---|---|
| 2026-06-30 | -$44.78M 10-Q · filed 2026-08-13 |
| 2026-03-31 | -$41.46M 10-Q · filed 2026-05-07 |
| 2025-12-31 | -$38.96M 10-Q · filed 2026-08-13 |
| 2025-09-30 | -$35.92M 10-Q · filed 2025-11-10 |
| 2025-06-30 | -$33.24M 10-Q · filed 2025-08-11 |
| 2025-03-31 | -$29.57M 10-Q · filed 2025-05-08 |
| 2024-12-31 | -$25.72M 10-K · filed 2026-03-31 |
| 2024-09-30 | -$21.54M 10-Q · filed 2024-11-07 |
| 2024-06-30 | -$19.13M 10-Q · filed 2024-08-07 |
| 2024-03-31 | -$16.73M 10-Q · filed 2024-05-09 |
| 2023-12-31 | -$15.07M 10-K · filed 2025-03-13 |
| 2023-09-30 | -$13.93M 10-Q · filed 2023-11-09 |
| 2023-06-30 | -$12.89M 10-Q · filed 2023-08-10 |
| 2023-03-31 | -$11.89M 10-Q · filed 2023-05-10 |
| 2022-12-31 | -$6.71M 10-K · filed 2024-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| Onconetix, Inc. (ONCO) | United States | $0.004B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B |